Background. Both rhGM-CSF and rhG-CSF can accelerate hematological recovery after high-dose therapy and autologous bone marrow transplantation in patients with high grade non Hodgkin's lymphoma and reduce transplant-related morbidity after ABMT. Methods. The clinical course of 23 non randomized patients was analyzed and compared with a historical control group of 10 patients. Ten patients received GM-CSF at a dose of 10 μg/kg in a 6-h IV infusion, and 13 received G-CSF at a dose of 5 μg/kg subcutaneously. Control patients received no GFs. Results. Mean granulocytic recovery to 0.5 x 109/L was obtained 13.1 ± 3.2 days after marrow reinfusion in the G-CSF arm vs 16 ± 2.7 in GM-CSF pts (p = 0.03) and vs 19.6 ± 7.6 in controls (p <0.01); this reduction led to a statistically significant shorter duration of fever and parenteral antibiotic therapy. Platelet recovery to 20 x 109/L was not significantly influenced by GFs. Conclusions. These results indicate that only G-CSF accelerates hematological recovery after high-dose chemotherapy and autologous bone marrow transplantation and induces a significant decrease in terms of infection morbidity and duration of hospital stay.
|Number of pages||8|
|Publication status||Published - 1994|
- autologous bone marrow transplantation
- growth factors
- high-grade non Hodgkin's lymphoma
ASJC Scopus subject areas